These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 22154022)

  • 1. Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia.
    Klimek VM; Dolezal EK; Smith L; Soff G; Nimer SD
    Leuk Res; 2012 May; 36(5):570-4. PubMed ID: 22154022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia - the biological heterogeneity.
    Bruserud Ø; Reikvam H
    Expert Opin Ther Targets; 2010 Nov; 14(11):1139-42. PubMed ID: 20942744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
    Klimek VM; Fircanis S; Maslak P; Guernah I; Baum M; Wu N; Panageas K; Wright JJ; Pandolfi PP; Nimer SD
    Clin Cancer Res; 2008 Feb; 14(3):826-32. PubMed ID: 18245545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear factor-kappaB modulation in patients undergoing induction chemotherapy for acute myelogenous leukemia.
    Strair RK; Gharibo M; Schaar D; Rubin A; Harrison J; Aisner J; Lin HC; Lin Y; Goodell L; Anand M; Balsara B; Dudek L; Rabson A; Medina DJ
    Clin Cancer Res; 2008 Nov; 14(22):7564-8. PubMed ID: 19010875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy.
    Zheng L; Howell SJ; Hatala DA; Huang K; Kern TS
    Diabetes; 2007 Feb; 56(2):337-45. PubMed ID: 17259377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Fabre C; Carvalho G; Tasdemir E; Braun T; Adès L; Grosjean J; Boehrer S; Métivier D; Souquère S; Pierron G; Fenaux P; Kroemer G
    Oncogene; 2007 Jun; 26(28):4071-83. PubMed ID: 17213804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
    Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E
    Cancer; 2003 Mar; 97(5):1234-41. PubMed ID: 12599230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia.
    Breccia M; Alimena G
    Expert Opin Ther Targets; 2010 Nov; 14(11):1157-76. PubMed ID: 20858024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
    Mattiuzzi GN; Kantarjian H; O'Brien S; Kontoyiannis DP; Giles F; Zhou X; Lim J; Bekele BN; Faderl S; Cortes J; Pierce S; Leitz GJ; Raad I; Estey E
    Cancer; 2004 Feb; 100(3):568-73. PubMed ID: 14745874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium salicylate inhibits TNF-alpha-induced NF-kappaB activation, cell migration, invasion and ICAM-1 expression in human melanoma cells.
    Katerinaki E; Haycock JW; Lalla R; Carlson KE; Yang Y; Hill RP; Lorigan PC; MacNeil S
    Melanoma Res; 2006 Feb; 16(1):11-22. PubMed ID: 16432451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Giles FJ; Kantarjian HM; Cortes JE; Faderl S; Verstovsek S; Thomas D; Garcia-Manero G; Wierda W; Ferrajoli A; Kornblau S; Mattiuzzi GN; Tsimberidou AM; Albitar M; O'Brien SM; Estey E
    Leuk Res; 2005 Jun; 29(6):649-52. PubMed ID: 15863204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
    Mattiuzzi GN; Kantarjian H; Faderl S; Lim J; Kontoyiannis D; Thomas D; Wierda W; Raad I; Garcia-Manero G; Zhou X; Ferrajoli A; Bekele N; Estey E
    Cancer; 2004 Feb; 100(3):581-9. PubMed ID: 14745876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
    Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
    Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.
    Löwenberg B; Morgan G; Ossenkoppele GJ; Burnett AK; Zachée P; Dührsen U; Dierickx D; Müller-Tidow C; Sonneveld P; Krug U; Bone E; Flores N; Richardson AF; Hooftman L; Jenkins C; Zweegman S; Davies F
    J Clin Oncol; 2010 Oct; 28(28):4333-8. PubMed ID: 20733120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose cytosine arabinoside (LD-Ara C) treatment in dysmyelopoietic syndromes (DMPS) and acute myelogenous leukemia (AML).
    Jehn U; Göldel N; Vehling-Kaiser U
    Anticancer Res; 1987; 7(3 Pt B):505-8. PubMed ID: 3477124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study.
    Kuriya S; Murai K; Miyairi Y; Utsugisawa T; Narigasawa Y; Ito T; Shimosegawa K; Ishida Y
    Cancer; 1996 Aug; 78(3):422-6. PubMed ID: 8697386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of acute recurrent benign pericarditis in a patient with glucose-6-phosphate dehydrogenase deficiency, treated with sodium salicylate].
    Tedeschini RC; Ruggiano G; Sofo D; Poggesi L
    Ann Ital Med Int; 2000; 15(2):166-8. PubMed ID: 10920507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
    Hu Q; Dey AL; Yang Y; Shen Y; Jilani IB; Estey EH; Kantarjian HM; Giles FJ; Albitar M
    Cancer; 2004 May; 100(9):1884-91. PubMed ID: 15112269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.